|
[1]
|
Zhang, Z.X., Dong, Z.H. and Roman, G.C. (2006) Early descriptions of Parkinson disease in ancient China. Archives of Neurology, 5, 782-784.
doi:10.1001/archneur.63.5.782
|
|
[2]
|
Manyam, B.V. (1990) Paralysis agitans and levodopa in “Ayurveda”: Ancient Indian medical treatise. Movement Disorders, 1, 47-48. doi:10.1002/mds.870050112
|
|
[3]
|
Dorsey, E.R., Constantinescu, R., Thompson, J.P., Biglan, K.M., Holloway, R.G., Kieburtz, K., Marshall, F.J., Ravina, B.M., Schifitto, G., Siderowf, A. and Tanner, C.M. (2007) Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030. Neurology, 5, 384-386.
doi:10.1212/01.wnl.0000247740.47667.03
|
|
[4]
|
Vollmer, H. (1942) Comparative value of solanaceus alka- loids in treatment of Parkinson’s syndrome. Archives of Neurology and Psychiatry, 48, 72-84.
|
|
[5]
|
Meter, J.R.V. (1950) Therapy of Parkinson’s disease. California Medicine, 4, 322-324.
|
|
[6]
|
Sano, I., Gamo, T. and Kakimoto, Y. (1959) Distribution of cathecol compounds in human brain. Biochemica et Biophysica Acta, 32, 586-587.
doi:10.1016/0006-3002(59)90652-3
|
|
[7]
|
Bertler, A. (1959) Ocurrence and distribution of dopamine in brain and other issues. Experientia, 15, 10-11.
doi:10.1007/BF02157069
|
|
[8]
|
Hornykiewicz, O. and Ehringer, J. (1960) Verteilung von noradrenalin and dopamin im gehirn des menschen und ihr verhalten bei erkrankungen des extrapyramidalen systems. Klinische Wochenschrift, 38, 1126-1239.
|
|
[9]
|
Birkmayer, W. and Hornykiewicz, O. (1961) The L-3,4- dioxyphenylalanine (DOPA)-effect in Parkinson-akinesia. Wiener Klinische Wochenschrift, 73, 787-788.
|
|
[10]
|
Cotzias, G.C., Van Woert, M.H. and Schiffer, L.M. (1967) Aromatic amino acids and modification of parkinsonism. The New England Journal of Medicine, 7, 374-379.
doi:10.1056/NEJM196702162760703
|
|
[11]
|
Ansari, K.A. and Johnson, A. (1975) Olfactory function in patients with Parkin-son's disease. Journal of Chronic Diseases, 9, 493-497.
doi:10.1016/0021-9681(75)90058-2
|
|
[12]
|
Doty, R.L., Golbe, L.I., McKeown, D.A., Stern, M.B., Lehrach, C.M. and Craw-ford, D. (1993) Olfactory testing differentiates between progressive supranuclear palsy and idiopathic Parkinson’s disease. Neurology, 5, 962-965.
doi:10.1212/WNL.43.5.962
|
|
[13]
|
Doty, R.L. (2012) Olfactory dysfunction in Parkinson disease. Nature Reviews Neurology, 6, 329-339.
|
|
[14]
|
Del Tredici, K., Rub, U., De Vos, R.A., Bohl, J.R. and Braak, H. (2002) Where does parkinson disease pathology begin in the brain? Journal of Neuropathology & Experimental Neurology, 5, 413-426.
|
|
[15]
|
Postuma, R.B. and Montplaisir, J. (2009) Predicting Parkinson's disease—why, when, and how? Parkinsonism & Related Disorders, 15, S105-S109.
doi:10.1016/S1353-8020(09)70793-X
|
|
[16]
|
Ravina, B., Camicioli, R., Como, P.G., Marsh, L., Jankovic, J., Weintraub, D. and Elm, J. (2007) The impact of depressive symptoms in early Parkinson disease. Neurology, 4, 342-347.
doi:10.1212/01.wnl.0000268695.63392.10
|
|
[17]
|
Schapira, A.H. (2010) Future strategies for neuroprotec- tion in Parkinson's disease. Neurodegenerative Disease, 1-3, 210-212. doi:10.1159/000295666
|
|
[18]
|
Postuma, R.B., Gagnon, J.F., Vendette, M. and Montplaisir, J.Y. (2009) Markers of neurodegeneration in idiopathic rapid eye movement sleep behaviour disorder and Parkinson’s disease. Brain, Pt 12, 3298-3307.
doi:10.1093/brain/awp244
|
|
[19]
|
Forno, L.S. (1996) Neuropa-thology of Parkinson’s disease. Journal of Neuropathology & Experimental Neurology, 3, 259-272.
doi:10.1097/00005072-199603000-00001
|
|
[20]
|
Jellinger, K.A. (2003) Alpha-synuclein pathology in Parkinson’s and Alz-heimer’s disease brain: Incidence and topographic distribu-tion—A pilot study. Acta Neuropa- thologica, 3, 191-201. doi:10.1007/s00401-003-0725-y
|
|
[21]
|
Ohama, E. and Ikuta, F. (1976) Parkinson’s disease: Distribution of Lewy bodies and monoamine neuron system. Acta Neuropathologica, 4, 311-319.
doi:10.1007/BF00696560
|
|
[22]
|
Braak, H., Del Tredici, K., Bratzke, H., Hamm-Clement, J., Sandmann-Keil, D. and Rub, U. (2002) Staging of the intracerebral inclusion body pathology associated with idiopathic Parkinson’s disease (preclinical and clinical stages). Journal of Neurology, 3, 1-5.
doi:10.1007/s00415-002-1301-4
|
|
[23]
|
Dickson, D.W., Braak, H., Duda, J.E., Duyckaerts, C., Gasser, T., Halliday, G.M., Hardy, J., Leverenz, J.B., Del Tredici, K., Wszolek, Z.K. and Litvan, I. (2009) Neuropathological assessment of Parkinson’s disease: Refining the diagnostic criteria. The Lancet Neurology, 12, 1150- 1157. doi:10.1016/S1474-4422(09)70238-8
|
|
[24]
|
Lewy (1919) Pa-ralysis agitans. I. pathologische anatomie. In: Lewandowsky, M., Ed., Hundbuch der Neurologie, 920-933.
|
|
[25]
|
Tretiakoff (1919) Contribution a L’étude de L’anatomie Pathologique de Locus Niger de Soemmerling. Université de Paris, Paris.
|
|
[26]
|
Xia, Q., Liao, L., Cheng, D., Duong, D.M., Gearing, M., Lah, J.J., Levey, A.I. and Peng, J. (2008) Proteomic identification of novel proteins associated with Lewy bodies. Frontiers in Bioscience, 13, 3850-3856. doi:10.2741/2973
|
|
[27]
|
Wakabayashi, K., Takahashi, H., Obata, K. and Ikuta, F. (1992) Immunocytochemical localization of synaptic vesicle-specific protein in Lewy body-containing neurons in Parkinson's disease. Neuroscience Letters, 2, 237-240.
doi:10.1016/0304-3940(92)90923-U
|
|
[28]
|
Spillantini, M.G., Schmidt, M.L., Lee, V. M., Trojanowski, J.Q., Jakes, R. and Goedert, M. (1997) Alpha-synuclein in Lewy bodies. Nature, 6645, 839-840. doi:10.1038/42166
|
|
[29]
|
Iwai, A., Masliah, E., Yoshimoto, M., Ge, N., Flanagan, L., de Silva, H.A., Kittel, A. and Saitoh, T. (1995) The precursor protein of non—A beta component of Alzheimer’s disease amyloid is a presynaptic protein of the central nervous system. Neuron, 2, 467-475.
doi:10.1016/0896-6273(95)90302-X
|
|
[30]
|
Baba, M., Nakajo, S., Tu, P.H., Tomita, T., Nakaya, K., Lee, V.M., Trojanowski, J.Q. and Iwatsubo, T. (1998) Aggregation of alpha-synuclein in Lewy bodies of sporadic Parkinson’s disease and dementia with Lewy bodies. American Journal of Pathology, 4, 879-884.
|
|
[31]
|
Hashimoto, M., Hsu, L.J., Xia, Y., Takeda, A., Sisk, A., Sundsmo, M. and Masliah, E. (1999) Oxidative stress induces amyloid-like aggregate formation of NACP/alpha- synuclein in vitro. Neuroreport, 4, 717-721.
doi:10.1097/00001756-199903170-00011
|
|
[32]
|
Fujiwara, H., Hasegawa, M., Dohmae, N., Kawashima, A., Masliah, E., Goldberg, M.S., Shen, J., Takio, K. and Iwatsubo, T. (2002) alpha-Synuclein is phosphorylated in synucleinopathy lesions. Nature Cell Biology, 2, 160-164.
|
|
[33]
|
Sevcsik, E., Trexler, A.J., Dunn, J.M. and Rhoades, E. (2011) Allostery in a disordered protein: Oxidative modifications to alpha-synuclein act distally to regulate membrane binding. Journal of the American Chemical Society, 18, 7152-7158. doi:10.1021/ja2009554
|
|
[34]
|
Somogyi, A., Rosta, K., Pusztai, P., Tulassay, Z. and Nagy, G. (2007) Antioxidant measurements. Physiological Measurement, 4, R41-55. doi:10.1088/0967-3334/28/4/R01
|
|
[35]
|
Segura-Aguilar, J. and Lind, C. (1989) On the mechanism of the Mn3(+)-induced neurotoxicity of dopamine: Pre- vention of quinone-derived oxygen toxicity by DT diaphorase and superoxide dismutase. Chemico-Biological Interactions, 3, 309-324.
doi:10.1016/0009-2797(89)90006-9
|
|
[36]
|
Napolitano, A., Manini, P. and d’Ischia, M. (2011) Oxidation chemistry of catecholamines and neuronal degeneration: An update. Current Medicinal Chemistry, 12, 1832- 1845. doi:10.2174/092986711795496863
|
|
[37]
|
Gerlach, M., Double, K.L., Ben-Shachar, D., Zecca, L., Youdim, M.B. and Riederer, P. (2003) Neuromelanin and its interaction with iron as a potential risk factor for dopaminergic neurodegeneration underlying Parkinson’s disease. Neurotoxicity Research, 1-2, 35-44.
doi:10.1007/BF03033371
|
|
[38]
|
Fasano, M., Bergamasco, B. and Lopiano, L. (2006) Modi- fications of the iron-neuromelanin system in Parkinson’s disease. Journal of Neurochemistry, 4, 909-916.
doi:10.1111/j.1471-4159.2005.03638.x
|
|
[39]
|
Wolozin, B. and Golts, N. (2002) Iron and Parkinson’s disease. Neuroscientist, 1, 22-32.
doi:10.1177/107385840200800107
|
|
[40]
|
Zecca, L., Tampellini, D., Gerlach, M., Riederer, P., Fariello, R.G. and Sulzer, D. (2001) Substantia nigra neuromelanin: structure, synthesis, and molecular behaviour. Molecular Pathology, 6, 414-418.
|
|
[41]
|
Ostrerova-Golts, N., Petrucelli, L., Hardy, J., Lee, J.M., Farer, M. and Wolozin, B. (2000) The A53T alpha-synu- clein mutation increases iron-dependent aggregation and toxicity. The Journal of Neuroscience, 16, 6048-6054.
|
|
[42]
|
Turnbull, S., Tabner, B.J., El-Agnaf, O.M., Moore, S., Davies, Y. and Allsop, D. (2001) alpha-Synuclein implicated in Parkinson’s disease catalyses the formation of hydrogen peroxide in vitro. Free Radical Biology & Medicine, 10, 1163-1170.
doi:10.1016/S0891-5849(01)00513-5
|
|
[43]
|
Shamoto-Nagai, M., Maruyama, W., Yi, H., Akao, Y., Tribl, F., Gerlach, M., Osawa, T., Riederer, P. and Naoi, M. (2006) Neuromelanin induces oxidative stress in mi- tochondria through release of iron: Mechanism behind the inhibition of 26S proteasome. Journal of Neural Transmission, 5, 633-644. doi:10.1007/s00702-005-0410-5
|
|
[44]
|
Braak, H., Ghebremedhin, E., Rub, U., Bratzke, H. and Del Tredici, K. (2004) Stages in the development of Parkinson’s disease-related pathology. Cell and Tissue Research, 1, 121-134. doi:10.1007/s00441-004-0956-9
|
|
[45]
|
Uchiyama, M., Isse, K., Tanaka, K., Yokota, N., Hamamoto, M., Aida, S., Ito, Y., Yoshimura, M. and Okawa, M. (1995) Incidental Lewy body disease in a patient with REM sleep behavior disorder. Neurology, 4, 709-712.
doi:10.1212/WNL.45.4.709
|
|
[46]
|
Turner, R.S., D’Amato, C.J., Chervin, R.D. and Blaivas, M. (2000) The pathology of REM sleep behavior disorder with comorbid Lewy body dementia. Neurology, 11, 1730- 1732. doi:10.1212/WNL.55.11.1730
|
|
[47]
|
Boeve, B.F., Silber, M.H., Saper, C.B., Ferman, T.J., Dickson, D.W., Parisi, J.E., Benarroch, E.E., Ahlskog, J.E., Smith, G.E., Caselli, R.C., Tippman-Peikert, M., Olson, E.J., Lin, S.C., Young, T., Wszolek, Z., Schenck, C. H., Mahowald, M.W., Castillo, P.R., Del Tredici, K. and Braak, H. (2007) Pathophysiology of REM sleep behaviiour disorder and relevance to neurodegenerative disease. Brain, Pt 11, 2770-2788. doi:10.1093/brain/awm056
|
|
[48]
|
Alexander, G.E., DeLong, M.R. and Strick, P.L. (1986) Parallel organization of functionally segregated circuits linking basal ganglia and cortex. Annual Review of Neuroscience, 9, 357-381.
doi:10.1146/annurev.ne.09.030186.002041
|
|
[49]
|
Albin, R.L., Young, A.B. and Penney, J.B. (1989) The functional anatomy of basal ganglia disorders. Trends in Neurosciences, 10, 366-375.
doi:10.1016/0166-2236(89)90074-X
|
|
[50]
|
DeLong, M.R. (1990) Primate models of movement dis- orders of basal ganglia origin. Trends in Neurosciences, 7, 281-285. doi:10.1016/0166-2236(90)90110-V
|
|
[51]
|
Bamford, N.S., Robinson, S., Palmiter, R.D., Joyce, J.A., Moore, C. and Meshul, C.K. (2004) Dopamine modulates release from corticostriatal terminals. The Journal of Neuroscience, 43, 9541-9552.
doi:10.1523/JNEUROSCI.2891-04.2004
|
|
[52]
|
Gerfen, C.R., Engber, T.M., Mahan, L.C., Susel, Z., Chase, T.N., Monsma, F.J., Jr. and Sibley, D.R. (1990) D1 and D2 dopamine receptor-regulated gene expression of striatonigral and striatopallidal neurons. Science, 4986, 1429-1432. doi:10.1126/science.2147780
|
|
[53]
|
Kravitz, A.V., Freeze, B.S., Parker, P.R., Kay, K., Thwin, M.T., Deisseroth, K. and Kreitzer, A.C. (2010) Regulation of parkinsonian motor behaviours by optogenetic control of basal ganglia circuitry. Nature, 7306, 622-626.
doi:10.1038/nature09159
|
|
[54]
|
Kempster, P.A., O’Sullivan, S.S., Holton, J.L., Revesz, T. and Lees, A.J. (2010) Relationships between age and late progression of Parkinson’s disease: A clinico-pathological study. Brain, Pt 6, 1755-1762. doi:10.1093/brain/awq059
|
|
[55]
|
Scarpa, M., Rigo, A., Maiorino, M., Ursini, F. and Grego- lin, C. (1984) Formation of al-pha-tocopherol radical and recycling of alpha-tocopherol by ascorbate during peroxidation of phosphatidylcholine lipo-somes. An electron paramagnetic resonance study. Biochimica et Biophysica Acta, 2, 215-219. doi:10.1016/0304-4165(84)90070-9
|
|
[56]
|
Lew, M.F. (2011) The evidence for disease modification in Parkinson’s disease. International Journal of Neuroscience, 121, 18-26. doi:10.3109/00207454.2011.620194
|
|
[57]
|
Fahn, S. (1991) An open trial of high-dosage antioxidants in early Parkinson’s disease. The American Journal of Clinical Nutrition, 1, 380S-382S.
|
|
[58]
|
Burne, T.H., McGrath, J.J., Eyles, D.W. and Mackay-Sim, A. (2005) Behavioural characterization of vitamin D receptor knockout mice. Behavioural Brain Research, 2, 299-308. doi:10.1016/j.bbr.2004.07.008
|
|
[59]
|
Baluchnejadmojarad, T., Roghani, M., Nadoushan, M.R. and Bagheri, M. (2009) Neuroprotective effect of genistein in 6-hydroxydopamine hemi-parkinsonian rat model. Phytotherapy Research, 1, 132-135. doi:10.1002/ptr.2564
|
|
[60]
|
Bousquet, M., Calon, F. and Cicchetti, F. (2011) Impact of omega-3 fatty acids in Park-inson's disease. Ageing Research Reviews, 4, 453-463.
doi:10.1016/j.arr.2011.03.001
|
|
[61]
|
Chang, Y.L., Chen, S.J., Kao, C.L., Hung, S.C., Ding, D.C., Yu, C.C., Chen, Y.J., Ku, H.H., Lin, C.P., Lee, K.H. Y., Chen, C., Wang, J.J., Hsu, C.C., Chen, L.K., Li, H.Y. and Chiou, S.H. (2012) Docosahexaenoic acid promotes dopaminergic differentiation in induced pluripo-tent stem cells and inhibits teratoma formation in rats with Parkinson-like pathology. Cell Transplantation, 1, 313-332.
|
|
[62]
|
Sakayori, N., Maekawa, M., Numayama-Tsuruta, K., Katura, T., Moriya, T. and Osumi, N. (2011) Distinctive effects of arachidonic acid and docosahexaenoic acid on neural stem /progenitor cells. Genes Cells, 7, 778-790.
doi:10.1111/j.1365-2443.2011.01527.x
|
|
[63]
|
Li, S.C., Schoen-berg, B.S., Wang, C.C., Cheng, X.M., Rui, D.Y., Bolis, C.L. and Schoenberg, D.G. (1985) A prevalence survey of Parkinson’s disease and other movement disorders in the People’s Republic of China. Archives of Neurology, 7, 655-657.
doi:10.1001/archneur.1985.04060070045013
|
|
[64]
|
Zhang, Z.X. and Roman, G.C. (1993) Worldwide occur- rence of Parkinson’s disease: An updated review. Neuroepidemiology, 4, 195-208. doi:10.1159/000110318
|
|
[65]
|
Barranco Quintana, J.L., Allam, M.F., Del Castillo, A.S. and Navajas, R.F. (2009) Parkinson’s disease and tea: A quantitative review. Journal of the American College of Nutrition, 1, 1-6.
|
|
[66]
|
Zhang, X., Xie, W., Qu, S., Pan, T., Wang, X. and Le, W. (2005) Neuroprotection by iron chelator against proteasome inhibitor-induced nigral degeneration. Biochemical and Biophysical Research Communication, 2, 544-549.
doi:10.1016/j.bbrc.2005.05.150
|
|
[67]
|
Gal, M., Hromadova, M., Pospisil, L., Hives, J., Sokolova, R., Kolivoska, V. and Bulickova, J. (2010) Voltammetry of hypoxic cells radiosensitizer etanidazole radical anion in water. Bioelectrochemistry, 2, 118-123.
doi:10.1016/j.bioelechem.2009.08.008
|
|
[68]
|
Ghosh, B., Antonio, T., Reith, M.E. and Dutta, A.K. (2010) Discovery of 4-(4-(2-((5-Hydroxy-1,2,3,4-tetra-hydronaphtha-len-2-yl)(propyl)amino)ethyl)piperazin-1-yl) quinolin-8-ol and its analogues as highly potent dopamine D2/D3 agonists and as iron chelator: In vivo activity indicates potential application in symptomatic and neuro- protective therapy for Parkinson’s disease. Journal of the Medicinal Chemistry, 5, 2114-2125.
doi:10.1021/jm901618d
|
|
[69]
|
Ascherio, A., Weisskopf, M.G., O’Reilly, E.J., McCullough, M.L., Calle, E.E., Rodriguez, C. and Thun, M.J. (2004) Coffee consumption, gender, and Parkinson’s dis- ease mortality in the cancer prevention study II cohort: The modifying effects of estrogen. American Journal of Epidemiology, 10, 977-984. doi:10.1093/aje/kwh312
|
|
[70]
|
Fredholm, B.B., Battig, K., Holmen, J., Nehlig, A. and Zvartau, E.E. (1999) Actions of caffeine in the brain with special reference to factors that contribute to its widespread use. Pharmacological Reviews, 1, 83-133.
|
|
[71]
|
Trinh, K., Andrews, L., Krause, J., Hanak, T., Lee, D., Gelb, M. and Pallanck, L. (2010) Decaffeinated coffee and nicotine-free tobacco provide neuroprotection in Drosophila models of Parkinson’s disease through an NRF2-dependent mechanism. The Journal of Neuroscience, 16, 5525-5532.
doi:10.1523/JNEUROSCI.4777-09.2010
|
|
[72]
|
Simoes, A.P., Duarte, J.A., Agasse, F., Canas, P.M., Tome, A.R., Agostinho, P. and Cunha, R.A. (2012) Blockade of adenosine A2A receptors prevents interleukin-1beta-induced exacerbation of neuronal toxicity through a p38 mitogen-activated protein kinase pathway. Journal of Neuroinflammation, 204. doi:10.1186/1742-2094-9-204
|
|
[73]
|
Alfinito, P.D., Wang, S.P., Manzino, L., Rijhsinghani, S., Zeevalk, G.D. and Sonsalla, P.K. (2003) Adenosinergic protection of dopaminergic and GABAergic neurons against mitochondrial inhibition through receptors located in the substantia nigra and striatum, respectively. The Journal of Neuroscience, 34, 10982-10987.
|
|
[74]
|
Birkmayer, W., Riederer, P., Youdim, M.B. and Linauer, W. (1975) The potentiation of the anti akinetic effect after L-dopa treatment by an inhibitor of MAO-B, Deprenil. Journal of Neural Transmission, 3-4, 303-326.
doi:10.1007/BF01253131
|
|
[75]
|
Riederer, P. and Laux, G. (2011) MAO-inhibitors in Parkinson’s disease. Experimental Neurobiology, 1, 1-17.
|
|
[76]
|
Jenner, P. and Langston, J.W. (2011) Explaining ADAGIO: A critical review of the biological basis for the clinical effects of rasagiline. Movement Disorders, 13, 2316-2323. doi:10.1002/mds.23926
|
|
[77]
|
Nyholm, D., Johansson, A., Lennernas, H. and Askmark, H. (2012) Levodopa infusion combined with entacapone or tolcapone in Parkinson disease: A pilot trial. European Journal of Neurology, 6, 820-826.
doi:10.1111/j.1468-1331.2011.03614.x
|
|
[78]
|
Hauser, R.A., Schapira, A.H., Rascol, O., Barone, P., Mizuno, Y., Salin, L., Haaksma, M., Juhel, N. and Poewe, W. (2010) Randomized, double-blind, multicenter evalua- tion of pramipexole extended release once daily in early Parkinson's disease. Movement Disorders, 15, 2542-2549.
doi:10.1002/mds.23317
|
|
[79]
|
Whone, A.L., Watts, R.L., Stoessl, A.J., Davis, M., Reske, S., Nahmias, C., Lang, A.E., Rascol, O., Ribeiro, M.J., Remy, P., Poewe, W.H., Hauser, R.A. and Brooks, D.J. (2003) Slower progression of Parkinson’s disease with ropinirole versus levodopa: The REAL-PET study. Annals of Neurology, 1, 93-101. doi:10.1002/ana.10609
|
|
[80]
|
(2003) A controlled trial of rotigotine monotherapy in early Parkinson’s disease. Archives of Neurology, 12, 1721- 1728.
|
|
[81]
|
Jones, C.A., Johnston, L.C., Jackson, M.J., Smith, L.A., van Scharrenburg, G., Rose, S., Jenner, P.G. and McCreary, A.C. (2010) An in vivo pharmacological evaluation of pardoprunox (SLV308)—a novel combined dopamine D(2)/D(3) receptor partial agonist and 5-HT(1A) receptor agonist with efficacy in experimental models of Parkinson's disease. European Neuropsychopharmacology, 8, 582-593. doi:10.1016/j.euroneuro.2010.03.001
|
|
[82]
|
Rascol, O., Bronzova, J., Hauser, R.A., Lang, A.E., Sampaio, C., Theeuwes A. and van de Witte, S.V. (2012) Pardoprunox as adjunct therapy to levodopa in patients with Parkinson’s disease experiencing motor fluctuations: Results of a double-blind, randomized, placebo-controlled, trial. Parkinsonism & Related Disorders, 4, 370-376.
doi:10.1016/j.parkreldis.2011.12.006
|
|
[83]
|
Bonuccelli, U., Piccini, P. and Rabey, J.M. (2009) Old and new dopamine agonists in Parkinson’s disease: A reappraisal. Introduction. Parkinsonism & Related Disor- ders, 15, S1. doi:10.1016/S1353-8020(09)00312-5
|
|
[84]
|
Yoshioka, M., Tanaka, K., Miyazaki, I., Fujita, N., Higashi, Y., Asanuma, M. and Ogawa, N. (2002) The dopa-mine agonist cabergoline provides neuroprotection by activation of the glutathione system and scavenging free radicals. Neuroscience Research, 3, 259-267.
doi:10.1016/S0168-0102(02)00040-8
|
|
[85]
|
Katayama, S. (2001) Actigraph analysis of diurnal motor fluctuations during dopamine agonist therapy. European Neurology, 46, 11-17. doi:10.1159/000058048
|
|
[86]
|
Bracco, F., Battaglia, A., Chouza, C., Dupont, E., Gershanik, O., Marti Masso, J.F. and Montastruc, J.L. (2004) The long-acting dopamine receptor agonist cabergoline in early Parkinson’s disease: Final results of a 5-year, double-blind, levodopa-controlled study. CNS Drugs, 11, 733- 746. doi:10.2165/00023210-200418110-00003
|
|
[87]
|
Calabresi, P., Centonze, D., Gubellini, P., Pisani, A. and Bernardi, G. (2000) Acetylcholine-mediated modulation of striatal function. Trends Neuroscience, 3, 120-126.
doi:10.1016/S0166-2236(99)01501-5
|
|
[88]
|
Luginger, E., Wenning, G.K., Bosch, S. and Poewe, W. (2000) Beneficial effects of amantadine on L-dopa-induced dyskinesias in Parkinson’s disease. Movement Disorders, 5, 873-878.
doi:10.1002/1531-8257(200009)15:5<873::AID-MDS1017>3.0.CO;2-I
|
|
[89]
|
Crosby, N.J., Deane, K.H. and Clarke, C.E. (2003) Amantadine for dyskinesia in Parkinson’s disease. The Cochrane Database of Systematic Reviews, 2, CD003467.
|
|
[90]
|
Gorell, J.M., Rybicki, B.A., Johnson, C.C. and Peterson, E.L. (1999) Smoking and Parkinson’s disease: A dose-response relationship. Neurology, 1, 115-119.
doi:10.1212/WNL.52.1.115
|
|
[91]
|
Baron, J.A. (1986) Cigarette smoking and Parkinson’s disease. Neurology, 11, 1490-1496.
doi:10.1212/WNL.36.11.1490
|
|
[92]
|
Grandinetti, A., Morens, D.M., Reed, D. and MacEachern, D. (1994) Prospective study of cigarette smoking and the risk of developing idiopathic Parkinson’s disease. Ameri- can Journal of Epidemiology, 12, 1129-1138.
|
|
[93]
|
Morens, D.M., Grandinetti, A., Davis, J.W., Ross, G.W., White, L.R. and Reed, D. (1996) Evidence against the operation of selective mortality in explaining the associa- tion between cigarette smoking and reduced occurrence of idiopathic Parkinson disease. American Journal of Epidemiology, 4, 400-404.
doi:10.1093/oxfordjournals.aje.a008941
|
|
[94]
|
Thacker, E.L., O’Reilly, E.J., Weisskopf, M.G., Chen, H., Schwarzschild, M.A., McCullough, M.L., Calle, E.E., Thun, M.J. and Ascherio, A. (2007) Temporal relationship between cigarette smoking and risk of Parkinson disease. Neurology, 10, 764-768.
doi:10.1212/01.wnl.0000256374.50227.4b
|
|
[95]
|
Quik, M. (2004) Smoking, nicotine and Parkinson’s disease. Trends in Neuroscience, 9, 561-568.
doi:10.1016/j.tins.2004.06.008
|
|
[96]
|
Jeyarasasingam, G., Tompkins, L. and Quik, M. (2002) Stimulation of non-alpha7 nicotinic receptors partially protects dopaminergic neurons from 1-methyl-4-phenyl- pyridinium-induced toxicity in culture. Neuroscience, 2, 275-285. doi:10.1016/S0306-4522(01)00488-2
|
|
[97]
|
Ryan, R.E., Ross, S.A., Drago, J. and Loiacono, R.E. (2001) Dose-related neuroprotective effects of chronic nicotine in 6-hydroxydopamine treated rats, and loss of neuroprotection in alpha4 nicotinic receptor subunit knock-out mice. British Journal of Pharmacology, 8, 1650- 1656. doi:10.1038/sj.bjp.0703989
|
|
[98]
|
Soto-Otero, R., Mendez-Alvarez, E., Hermida-Ameijeiras, A., Lopez-Real, A.M. and Labandeira-Garcia, J.L. (2002) Effects of (-)-nicotine and (-)-cotinine on 6-hydroxy-do- pamine-induced oxidative stress and neurotoxicity: Relevance for Parkinson’s disease. Biochemical Pharmacol- ogy, 1, 125-135. doi:10.1016/S0006-2952(02)01070-5
|
|
[99]
|
Visanji, N.P., O’Neill, M.J. and Duty, S. (2006) Nicotine, but neither the alpha4beta2 ligand RJR2403 nor an alpha7 nAChR subtype selective agonist, protects against a partial 6-hydroxydopamine lesion of the rat median forebrain bundle. Neuropharmacology, 3, 506-516.
doi:10.1016/j.neuropharm.2006.04.015
|
|
[100]
|
Quik, M., Parameswaran, N., McCallum, S.E., Bordia, T., Bao, S., McCormack, A., Kim, A., Tyndale, R.F., Langston, J.W. and Di Monte, D.A. (2006) Chronic oral nicotine treatment protects against striatal degeneration in MPTP- treated primates. Journal of Neurochemistry, 6, 1866- 1875. doi:10.1111/j.1471-4159.2006.04078.x
|
|
[101]
|
Bordia, T., Parameswaran, N., Fan, H., Langston, J.W., McIntosh, J.M. and Quik, M. (2006) Partial recovery of striatal nicotinic receptors in 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP)-lesioned monkeys with chronic oral nicotine. Journal of Pharmacology and Experimental Therapeutics, 1, 285-292. doi:10.1124/jpet.106.106997
|
|
[102]
|
Costa, G., Abin-Carriquiry, J.A. and Dajas, F. (2001) Nicotine prevents striatal dopamine loss produced by 6-hydroxydopamine lesion in the substantia nigra. Brain Research, 2, 336-342.
doi:10.1016/S0006-8993(00)03087-0
|
|
[103]
|
Behmand, R.A. and Harik, S.I. (1992) Nicotine enhances 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine neurotoxicity. Journal of Neurochemistry, 2, 776-779.
doi:10.1111/j.1471-4159.1992.tb09786.x
|
|
[104]
|
Moll, H. (1926) The treatment of post-encephalitig park- insonism by nicotine. British Medical Journal, 3416, 1079-1081. doi:10.1136/bmj.1.3416.1079
|
|
[105]
|
Villafane, G., Cesaro, P., Rialland, A., Baloul, S., Azimi, S., Bourdet, C., Le Houezec, J., Macquin-Mavier, I. and Maison, P. (2007) Chronic high dose transdermal nicotine in Parkinson’s disease: An open trial. European Journal of Neurology, 12, 1313-1316.
doi:10.1111/j.1468-1331.2007.01949.x
|
|
[106]
|
Fagerstrom, K.O., Pomerleau, O., Giordani, B. and Stel- son, F. (1994) Nicotine may relieve symptoms of Parkin- son’s disease. Psychophar-macology (Berl), 1, 117-119.
doi:10.1007/BF02244882
|
|
[107]
|
Bordia, T., Campos, C., Huang, L. and Quik, M. (2008) Continuous and intermittent nicotine treatment reduces L-3,4-dihydroxyphenylalanine (L-DOPA)-induced dyski- nesias in a rat model of Parkinson’s disease. Journal of Pharmacology and Experimental Therapeutics, 1, 239- 247. doi:10.1124/jpet.108.140897
|
|
[108]
|
Picciotto, M.R. and Zoli, M. (2008) Neuroprotection via nAChRs: The role of nAChRs in neurodegenerative dis- orders such as Alzheimer’s and Parkinson’s disease. Frontiers in Bioscience, 13, 492-504. doi:10.2741/2695
|
|
[109]
|
Lindvall, O., Bjorklund, A. and Skagerberg, G. (1984) Selective histochemical demonstration of dopamine terminal systems in rat di- and telencephalon: new evidence for dopaminergic innervation of hypothalamic neuros cretory nuclei. Brain Research, 1-2, 19-30.
doi:10.1016/0006-8993(84)90352-4
|
|
[110]
|
Dehorter, N., Guigoni, C., Lopez, C., Hirsch, J., Eusebio, A., Ben-Ari, Y. and Hammond, C. (2009) Dopamine-deprived striatal GABAergic interneurons burst and gener- ate repetitive gigantic IPSCs in medium spiny neurons. The Journal of Neuroscience, 24, 7776-7787.
doi:10.1523/JNEUROSCI.1527-09.2009
|
|
[111]
|
Xiao, C., Nashmi, R., McKinney, S., Cai, H., McIntosh, J. M. and Lester, H.A. (2009) Chronic nicotine selectively enhances alpha4beta2* nicotinic acetylcholine receptors in the nigrostriatal dopamine pathway. The Journal of Neuroscience, 40, 12428-12439.
doi:10.1523/JNEUROSCI.2939-09.2009
|
|
[112]
|
Gittis, A.H., Leventhal, D.K., Fensterheim, B.A., Pettibone, J.R., Berke, J.D. and Kreitzer, A.C. (2011) Selective inhibition of striatal fast-spiking interneurons causes dyskinesias. The Journal of Neuroscience, 44, 15727- 15731. doi:10.1523/JNEUROSCI.3875-11.2011
|
|
[113]
|
Gregorio, M.L., Wietzikoski, E.C., Ferro, M.M., Silveira, J.L., Vital, M.A. and Da Cunha, C. (2009) Nicotine induces sensitization of turning behavior in 6-hydroxy-dopamine lesioned rats. Neurotoxicity Research, 4, 359-366.
doi:10.1007/s12640-009-9041-1
|
|
[114]
|
Zhao-Shea, R., Cohen, B.N., Just, H., McClure-Begley, T., Whiteaker, P., Grady, S.R., Salminen, O., Gardner, P.D., Lester, H.A. and Tapper, A.R. (2010) Dopamine D2-receptor activation elicits akinesia, rigidity, catalepsy, and tremor in mice expressing hypersensitive {alpha}4 nicotinic receptors via a cholinergic-dependent mechanism. The FASEB Journal, 1, 49-57. doi:10.1096/fj.09-137034
|
|
[115]
|
Kalivas, P.W., Churchill, L. and Klitenick, M.A. (1993) GABA and enkephalin projection from the nucleus ac- cumbens and ventral pallidum to the ventral tegmental area. Neuroscience, 4, 1047-1060.
doi:10.1016/0306-4522(93)90048-K
|
|
[116]
|
McGehee, D.S., Heath, M.J., Gelber, S., Devay, P. and Role, L.W. (1995) Nicotine enhancement of fast excitatory synaptic transmission in CNS by presynaptic recep- tors. Science, 5231, 1692-1696.
doi:10.1126/science.7569895
|
|
[117]
|
Ribeiro, E.B., Bettiker, R.L., Bogdanov, M. and Wurtman, R.J. (1993) Effects of systemic nicotine on serotonin re- lease in rat brain. Brain Research, 2, 311-318.
doi:10.1016/0006-8993(93)90121-3
|
|
[118]
|
Boyadjieva, N.I. and Sarkar, D.K. (1997) The secretory response of hypothalamic beta-endorphin neurons to acute and chronic nicotine treatments and following nicotine withdrawal. Life Science, 6, PL59-66.
|
|
[119]
|
Pierzchala, K., Houdi, A.A. and Van Loon, G.R. (1987) Nicotine-induced alterations in brain regional concentrations of native and cryptic Met- and Leu-enkephalin. Pep- tides, 6, 1035-1043. doi:10.1016/0196-9781(87)90133-1
|
|
[120]
|
de Rover, M., Lodder, J.C., Kits, K.S., Schoffelmeer, A.N. and Brussaard, A.B. (2002) Cholinergic modulation of nucleus accumbens medium spiny neurons. European Journal of Neuroscience, 12, 2279-2290.
doi:10.1046/j.1460-9568.2002.02289.x
|
|
[121]
|
Gittis, A.H., Nelson, A.B., Thwin, M.T., Palop, J.J. and Kreitzer, A.C. (2010) Distinct roles of GABAergic in- terneurons in the regulation of striatal output pathways. The Journal of Neuroscience, 6, 2223-2234.
doi:10.1523/JNEUROSCI.4870-09.2010
|
|
[122]
|
García-Montes, J.R., Boronat-García, A., López-Colomé, A.M., Bargas, J., Guerra-Crespo, M. and Drucker-Colín, R. (2012) Is nicotine protective against Parkinson’s disease? An experimental analysis. CNS & Neurological Disorders-Drug Targets, in press.
|